This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.
Practice Pearls: Clinical Trial Updates From ESMO 2025 Covering Antibody-drug Conjugates in Triple-negative Breast Cancer
This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.
Trending on Pharmacy Times
1
Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications
2
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
3
FDA Approves Reformulated Ranitidine After 5-Year Absence
4
Understanding Cyclobenzaprine Hydrochloride: An Emerging Therapy for Fibromyalgia
5
